




RealRate

PHARMACEUTICAL 2017

CONCERT PHARMACEUTICALS INC. Rank 83 of 292





RealRate

PHARMACEUTICAL 2017

CONCERT PHARMACEUTICALS INC. Rank 83 of 292

CoNCERT

The relative strengths and weaknesses of CONCERT PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CONCERT PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 119% points. The greatest weakness of CONCERT PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 168%, being 165% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	97,729
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,570
Liabilities, Non-Current	0
Other Assets	467
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	9,231
Other Net Income	447
Other Revenues	174
Property and Equipment	2,199
Research and Development	36,983
Selling, General and Administrative Expense	14,358

Output Variable	Value in 1000 USD
Assets	100,395
Liabilities	14,801
Expenses	51,341
Revenues	174
Stockholders Equity	85,594
Net Income	-50,720
Comprehensive Net Income	-50,720
Economic Capital Ratio	168%